drugset / Trial / NCT06133517
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Phase 2
Active not recruiting
70 enrolled
Fundación para el Progreso de la Oncología en Cantabria
Apices Soluciones S.L. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this trial is to evaluate the efficacy of the combo Sacituzumab govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as pathologic complete response (pCR) rates, in the perioperative setting in patients with Muscle Invasive Bladder Cancer (MIBC) who are either unfit for platinum-based chemotherapy or unwilling to receive that therapy.
Timeline
- Start
- 2025-01-20
- Primary completion
- 2030-01
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | 360 mg | Intravenous |